Nothing Special   »   [go: up one dir, main page]

PA8798401A1 - Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida - Google Patents

Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Info

Publication number
PA8798401A1
PA8798401A1 PA20088798401A PA8798401A PA8798401A1 PA 8798401 A1 PA8798401 A1 PA 8798401A1 PA 20088798401 A PA20088798401 A PA 20088798401A PA 8798401 A PA8798401 A PA 8798401A PA 8798401 A1 PA8798401 A1 PA 8798401A1
Authority
PA
Panama
Prior art keywords
benzimidazol
carboxamida
pirrolidin
methyl
crystal form
Prior art date
Application number
PA20088798401A
Other languages
English (en)
Inventor
Kolaczkowski Lawrence
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40210712&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8798401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PA8798401A1 publication Critical patent/PA8798401A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE DESCRIBE LA FORMA CRISTALINA 1 DE 2-((R)-2-METILPIRROLIDIN-2-IL)-1H-BENZIMIDAZOL-4-CARBOXAMIDA,FORMAS PARA ELABORARLA,COMPOSICIONES QUE LA COMPRENDEN Y ELABORADAS USÁNDOLA,Y MÉTODOS QUE LA USAN PARA EL TRATAMIENTO DE PACIENTES ENFERMOS.
PA20088798401A 2007-10-12 2008-10-10 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida PA8798401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US97964307P 2007-10-12 2007-10-12

Publications (1)

Publication Number Publication Date
PA8798401A1 true PA8798401A1 (es) 2009-05-15

Family

ID=40210712

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20088798401A PA8798401A1 (es) 2007-10-12 2008-10-10 Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida

Country Status (27)

Country Link
US (4) US8372987B2 (es)
EP (2) EP2212327A1 (es)
JP (4) JP2011500589A (es)
KR (2) KR20100090769A (es)
CN (2) CN101821270A (es)
AU (1) AU2008310781B2 (es)
BR (1) BRPI0816221A8 (es)
CA (2) CA2696424C (es)
CO (1) CO6280493A2 (es)
CR (1) CR11368A (es)
DK (1) DK2722046T3 (es)
DO (1) DOP2010000099A (es)
EC (1) ECSP10010150A (es)
ES (1) ES2620299T3 (es)
GT (1) GT201000080A (es)
MX (1) MX350019B (es)
MY (1) MY156691A (es)
NZ (1) NZ583209A (es)
PA (1) PA8798401A1 (es)
PL (1) PL2722046T3 (es)
PT (1) PT2722046T (es)
RU (2) RU2476434C2 (es)
SG (1) SG185297A1 (es)
TW (1) TWI422588B (es)
UA (2) UA113277C2 (es)
WO (1) WO2009049111A1 (es)
ZA (1) ZA201002090B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX350019B (es) 2007-10-12 2016-12-09 Abbvie Ireland Unlimited Co Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-bencimidaz ol-4-carboxamida.
CN101821269B (zh) 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
CN105130961B (zh) * 2015-08-06 2018-02-16 苏州晶云药物科技有限公司 Abt‑888的晶型b及其制备方法和应用
CN106995436A (zh) * 2016-01-25 2017-08-01 重庆医药工业研究院有限责任公司 一种维利帕尼晶型a及其制备方法
WO2017152846A1 (zh) * 2016-03-09 2017-09-14 苏州晶云药物科技有限公司 2-[(2r)-2-甲基-2-吡咯烷基]-1h-苯并咪唑-7-甲酰胺二盐酸盐的晶型a及其制备方法
EP3275434B1 (en) 2016-07-27 2020-08-26 Sandoz Ag An extended release oral dosage form

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK9742002A3 (en) * 2000-01-07 2003-02-04 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
EP1298125A1 (en) * 2001-09-26 2003-04-02 Aventis Pharma S.A. Substituted benzimidazole compounds and their use for the treatment of cancer
TWI375673B (en) * 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
MX350019B (es) 2007-10-12 2016-12-09 Abbvie Ireland Unlimited Co Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-bencimidaz ol-4-carboxamida.
CN101821269B (zh) * 2007-10-12 2014-05-28 艾伯维巴哈马有限公司 2-((r)-2-甲基吡咯烷-2-基)-1h-苯并咪唑-4-甲酰胺晶形2

Also Published As

Publication number Publication date
EP2722046A1 (en) 2014-04-23
BRPI0816221A2 (pt) 2015-06-16
UA101961C2 (en) 2013-05-27
DOP2010000099A (es) 2017-04-30
BRPI0816221A8 (pt) 2015-09-22
KR20100090769A (ko) 2010-08-17
KR20160039312A (ko) 2016-04-08
PT2722046T (pt) 2017-03-15
CR11368A (es) 2010-10-25
CA2696424C (en) 2018-07-10
AU2008310781B2 (en) 2013-03-28
MY156691A (en) 2016-03-15
EP2722046B1 (en) 2016-12-21
US8372987B2 (en) 2013-02-12
MX350019B (es) 2016-12-09
AU2008310781A1 (en) 2009-04-16
ECSP10010150A (es) 2010-06-29
DK2722046T3 (en) 2017-03-20
US20150148392A1 (en) 2015-05-28
JP2019001811A (ja) 2019-01-10
ZA201002090B (en) 2011-11-30
CA3006332A1 (en) 2009-04-16
RU2012147692A (ru) 2014-05-20
WO2009049111A1 (en) 2009-04-16
US20140024838A1 (en) 2014-01-23
RU2476434C2 (ru) 2013-02-27
CN105367554A (zh) 2016-03-02
MX2010003772A (es) 2010-04-21
ES2620299T3 (es) 2017-06-28
US9580410B2 (en) 2017-02-28
SG185297A1 (en) 2012-11-29
RU2010116397A (ru) 2011-11-20
PL2722046T3 (pl) 2017-06-30
US8835647B2 (en) 2014-09-16
NZ583209A (en) 2012-06-29
JP2014237659A (ja) 2014-12-18
JP2017071618A (ja) 2017-04-13
JP2011500589A (ja) 2011-01-06
TW200932747A (en) 2009-08-01
CN101821270A (zh) 2010-09-01
US20130123317A1 (en) 2013-05-16
CO6280493A2 (es) 2011-05-20
CA2696424A1 (en) 2009-04-16
GT201000080A (es) 2012-04-03
EP2212327A1 (en) 2010-08-04
UA113277C2 (xx) 2017-01-10
TWI422588B (zh) 2014-01-11
US20090099245A1 (en) 2009-04-16

Similar Documents

Publication Publication Date Title
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
BRPI1015569A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias.
SMP200900085B (it) 3-imidazolil-indoli per il trattamento di malattieproliferative.
BRPI0916862A2 (pt) compostos úteis para o tratamento de doenças degenerativas e inflamatórias
ECSP088210A (es) Bencimidazoles sustituidos y métodos de preparación
BRPI0816784A2 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
BRPI0807717A2 (pt) Inibidores de quinase úteis para o tratamento de doenças mieloproliferativas e outras doenças proliferativas.
BRPI0716844A2 (pt) Inidores de quinase úteis para o tratamento de doenças proliferativas
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
EA201170832A1 (ru) Пуриновые соединения
BRPI0911577A8 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
DK2056842T3 (da) Modificeret galactosylceramid til behandling af cancerøse sygdomme
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
BRPI0911612A2 (pt) composições e métodos para o tratamento da esclerose múltipla.
CL2007002920A1 (es) Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
BRPI1009783A2 (pt) compostos para o tratamento de distúrbios metabólicos.
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
IT1391866B1 (it) Composizione iniettabile di polinucleotidi per il trattamento di patologie osteoarticolari.
PA8798401A1 (es) Forma cristalina 1 de 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
CL2008000641A1 (es) Compuestos derivados de amidas sustituidas; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del insomnio, disfuncion sexual, esquizofrenia, entre otras enferme
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
CL2008000110A1 (es) Uso de compuestos derivados de piranona sustituidos para el tratamiento del sindrome metabolico; y compuestos derivados de piranona sustituidos.
BRPI1013245A2 (pt) "composto para o tratamento de distúrbios metabólicos"